Genetic testing by cancer site: Pancreas

Cancer Journal (United States)

Volumn 18, Issue 4, 2012, Pages 350-354

  Axilbund, Jennifer E ^a   Wiley, Elizabeth A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

familial cancer; genetics; hereditary syndrome; Pancreatic cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPITHELIAL CELL ADHESION MOLECULE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; EARLY DIAGNOSIS; FAMILY HISTORY; FANCONI ANEMIA; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAZARD RATIO; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; MELANOMA; MUTATIONAL ANALYSIS; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; WILD TYPE;

CARCINOMA; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PEUTZ-JEGHERS SYNDROME; RISK ASSESSMENT;

EID: 84864622853     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182624694     Document Type: Review

References (83)

1. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol. 1996;23:251Y275.
2. Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J. 2001;7:266Y273.
3. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634Y2638.
4. Klein AP, Beaty TH, BaileyYWilsonJE, et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol. 2002;23:133Y149.
5. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310Y1316.
6. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations [published online ahead of print December 21, 2011]. Fam Cancer.
7. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42:711Y719.
8. Kim DH, Crawford B, Ziegler J, et al. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer. 2009;8:153Y158.
9. Martin ST, Matsubayashi H, Rogers CD, et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene. 2005;24:3652Y3656.
10. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002;62:3789Y3793.
11. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95:214Y221.
12. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:342Y346.
13. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360Y5364.
14. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009;27: 433Y438.
15. Figer A, Irmin L, Geva R, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer. 2001;84:478Y481.
16. Stadler ZK, Salo-Mullen E, Patil SM, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012;118:493Y499.
17. Cho JH, Bang S, Park SW, et al. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group. Pancreas. 2008;36:337Y340.
18. Ghiorzo P, Pensotti V, Fornarini G, et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Fam Cancer. 2012;11:41Y47.
19. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358Y1365.
20. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365Y1372.
21. Al-Sukhni W, Rothenmund H, Borgida AE, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet. 2008;124:271Y278.
22. Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet. 2005;158:119Y125.
23. Danes BS, Lynch HT. A familial aggregation of pancreatic cancer. An in vitro study. JAMA. 1982;247:2798Y2802.
24. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009;8:131Y135.
25. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162Y164.
26. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159Y161.
27. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165Y167.
28. McInerney NM, Miller N, Rowan A, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat. 2010;121:203Y210.
29. Gunnarsson H, Arason A, Gillanders EM, et al. Evidence against PALB2 involvement in Icelandic breast cancer susceptibility. J Negat Results Biomed. 2008;7:5.
30. Papi L, Putignano AL, Congregati C, et al. A PALB2 germline mutation associatedwith hereditary breast cancer in Italy. Fam Cancer. 2010;9:181Y185.
31. Ding YC, Steele L, Chu LH, et al. Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat. 2011; 126:227Y230.
32. ZhengY, Zhang J,NiuQ, et al.Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012;118:1362Y1370.
33. Cao AY, Huang J, Hu Z, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;114:457Y462.
34. Blanco A, de la Hoya M, Balmaña J, et al. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat. 2012;132:307Y315.
35. Sluiter M, Mew S, van Rensburg EJ. PALB2 sequence variants in young South African breast cancer patients. Fam Cancer. 2009;8:347Y353.
36. Casadei S, Norquist BM,Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71:2222Y2229.
37. Tischkowitz M, Capanu M, Sabbaghian N, et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat. 2012;33:674Y680.
38. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to earlyonset breast cancer in French-Canadian women. Breast Cancer Res. 2007;9:R83.
39. Erkko H, Xia B, Nikkilä J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316Y319.
40. Erkko H, Dowty JG, Nikkilä J, et al. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res. 2008;14:4667Y4671.
41. Sabbaghian N, Kyle R, Hao A, et al. Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma. Fam Cancer. 2011;10: 315Y317.
42. Adank MA, van Mil SE, Gille JJ, et al. PALB2 analysis in BRCA2-like families. Breast Cancer Res Treat. 2011;127:357Y362.
43. Tischkowitz M, Sabbaghian N, Ray AM, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate. 2008;68:675Y678.
44. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324:217.
45. Harinck F, Kluijt I, van Mil SE, et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet. 2012;20: 577Y579.
46. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010;78:490Y494.
47. Stadler ZK, Salo-Mullen E, Sabbaghian N, et al. Germline PALB2 mutation analysis in breast-pancreas cancer families [published online ahead of print March 17, 2011]. J Med Genet. 2011;48:523Y525.
48. Peterlongo P, Catucci I, Pasquini G, et al. PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat. 2011;126:825Y828.
49. Kanda M, Matthaei H,Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730Y733.
50. Remmers N, Bailey JM, Mohr AM, et al. Molecular pathology of early pancreatic cancer. Cancer Biomark. 2011;9:421Y440.
51. Bartsch D, Shevlin DW, Tung WS, et al. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer. 1995;14:189Y195.
52. de Snoo FA, Bishop DT, BergmanW, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)Ypositive melanoma families. Clin Cancer Res. 2008;14:7151Y7157.
53. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87: 809Y811.
54. Mukherjee B, Delancey JO, Raskin L, et al. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers [published online ahead of print April 24, 2012]. J Natl Cancer Inst. 2012.
55. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011;19:472Y478.
56. Ghiorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet. 2012;49:164Y170.
57. Debniak T, van de Wetering T, Scott R, et al. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. Eur J Cancer Prev. 2008;17: 389Y391.
58. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer. 2011;10:323Y330.
59. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg. 2002;236:730Y737.
60. Lal G, Liu L, Hogg D, et al. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer. 2000;27:358Y361.
61. Goggins M, Offerhaus GJ, Hilgers W, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998; 152:1501Y1507.
62. Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 2001;61:3136Y3144.
63. Lynch HT, Voorhees GJ, Lanspa SJ, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer. 1985;52:271Y273.
64. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141Y149.
65. Geary J, Sasieni P, Houlston R, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer. 2008;7:163Y172.
66. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302:1790Y1795.
67. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214Y218.
68. Vasen HF, Offerhaus GJ, den Hartog Jager FH, et al. The tumor spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer. 1990;46:31Y34.
69. Gargiulo S, Torrini M, Ollila S, et al. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer. 2009;8:547Y553.
70. Howes N, Lerch MM, GreenhalfW, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252Y261.
71. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442Y446.
72. Rebours V, Boutron-Ruault MC, Schnee MF, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103:111Y119.
73. Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286:169Y170.
74. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000; 119:1447Y1453.
75. Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology. 2004; 126:1788Y1794.
76. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12: 3209Y3215.
77. Grützmann R, McFaul C, Bartsch DK, et al. No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett. 2004;214:63Y68.
78. Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer. 2010;127:1421Y1428.
79. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796Y804.
80. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946Y954.
81. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010;16:5028Y5037.
82. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009;58:1410Y1418.
83. Goggins M. Markers of pancreatic cancer: working toward early detection. Clin Cancer Res. 2011;17:635Y637.